Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA)

Table 2 Estimated changes in SUA concentration over 24 weeks

Time point	Estimated mean value	95% CI	P-value
Baseline	8.25	7.96 to 8.55
At week 4	6.48	6.18 to 6.78
Absolute change from baseline	− 1.77	− 2.09 to − 1.45	< 0.001
Percentage change from baseline	− 21.0%	− 24.8% to − 17.2%	< 0.001
At week 8	6.16	5.86 to 6.46
Absolute change from baseline	− 2.09	− 2.41 to − 1.77	< 0.001
Percentage change from baseline	− 24.3%	− 28.1% to − 20.5%	< 0.001
At week 12	5.16	4.86 to 5.46
Absolute change from baseline	− 3.10	− 3.41 to − 2.78	< 0.001
Percentage change from baseline	− 36.7%	− 40.6% to − 32.9%	< 0.001
At week 24	5.24	4.94 to 5.54
Absolute change from baseline	− 3.01	− 3.33 to − 2.69	< 0.001
Percentage change from baseline	− 35.8%	− 39.7% to − 32.0%	< 0.001

ISSN: 2047-783X